• Programme 2025
• Programme 2024
• Programme 2023
• Programme 2022
• Programme 2020
• CME 2020
• Programme 2019
• Programme 2018
• CME 2018
• Programme 2017
• CME 2017
• Programme 2016

Programme 2018

Wednesday 17th January 2018
Moderator: Hans Eiskjaer
16.00–16.25	Hepatitis C the beginning of the end; is it really all over?	Paolo Grossi Varese,Italy
16.25–16.50	Primary graft dysfunction biomarkers	Jason Christie Philadelphia, USA
16.50–17.10	Coffee break
17.10–17.35	Cell free DNA and rejection in Heart Transplantation	Jens Bohmer Gothenburg, Sweden
17.35–18.00	DCD in Lung Transplantation	Greg Snell Melbourne, Australia
18.00–19.00	Fascinating Failures and Surprising Successes-Case - 6 Case presentation sections (8 mins. Talk - 2 mins. Questions)
	18.00–18.10 Renal failure and VADS	Marie Hogan, Minnesota, USA
	18.10–18.20 We bet you have not seen such a case before	Anja Roden Minnesota, USA
	18.20–18.30 The ground glass dilemma	Erik Verschuuren Groningen, Netherlands
	18.30–18.40 Case series: –extended criteria– for lung transplant recipients.	Peter Riddell Dublin, Ireland
	18.40–18.50 TBC	Jose Gonzalez Costello Barcelona, Spain
	18.50–19.00 Bronchial dehiscence after lung transplant treated with VAC	Andreas Wallinder Gothenburg, Sweden
Thursday 18th January 2018
Moderator: Göran Dellgren
16.00–16.25	Biopsy differences and DCD vs DBD in Heart Transplantation	Martin Goddard Cambridge, UK
16.25–16.50	Unloading induced myocardial recovery: mechanistic insights into practical approach to LVAD weaning.	Joseph Stehlik Salt Lake City, USA
16.50–17.15	The clinical implications of the lung micro biome in Thoracic Transplantation	Sangeta Bhorade Chicago, USA
17.15–17.40	Donor selection based on Eplet matching in Lung Transplantation	Glen Westall Melbourne, Australia
17.40–18.00	Coffee break and business meeting during talks
18.00–19.00	WERNER ZUBER MEMORIAL LECTURE
	18.00–18.30 Physician climber	Dr Andy Peacock Glasgow, Scotland
	18.30–19.00 General discussion and Business meeting
Friday 19th January 2018
Moderator: Margaret Hannan
16.00–16.25	New data around Community Acquired Respiratory Viruses in Lung Transplantation	Jens Gottlieb Hannover, Germany
16.25–16.50	Choosing the best system for urgency excalation in Lung Transplantation in Europe	Are Holm Oslo, Norway
16.50–17.15	Ischemic reperfusion injury in thoracic transplantation – Is it really preventable?	Karl Lemstrom Helsinki, Finland
17.15–17.50	Coffee break
17.50–19.00	Young investigators (8 mins. Talk - 2 mins. Questions)
	17.50–18.00 Sequential lung transplant	Bassem Gadallah Dublin, Ireland
	18.00–18.10 Effects of short and long term cold static preservation followed by normothermic ex vivo lung perfusion in a porcine model	Carolin Olbertz Essen, Germany
	18.10–18.20 Surviving Cepacia Syndrome Post Lung Transplantation	Jana Kleinerova Dublin, Ireland
	18.20–18.30 Cardiac re-transplantation - A reasonable treatment option in selected patients with severe graft failure	Pia Dahlberg Gothenburg,Sweden
	18.30–18.40 Prognostic value of invasive resting and exercise hemodynamics in long-term heart-transplanted patients	Tor Skibsted Clemmensen Aarhus, Denmark
	18.40–18.50 The interleukin-33/ST2 pathway is expressed in the failing human heart and associated with pro-fibrotic	Manon Huibers Utrecht, Netherlands
	18.50–19.00 Optical coherence tomography	Michal Pazdernik Prague, Czech Republic